23.40
1.98 (9.24%)
| Previous Close | 21.42 |
| Open | 22.30 |
| Volume | 1,920,290 |
| Avg. Volume (3M) | 1,256,214 |
| Market Cap | 2,388,321,024 |
| Price / Book | 5.64 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 21 May 2025 |
| Diluted EPS (TTM) | -9.28 |
| Total Debt/Equity (MRQ) | 8.64% |
| Current Ratio (MRQ) | 3.49 |
| Operating Cash Flow (TTM) | -582.45 M |
| Levered Free Cash Flow (TTM) | -364.16 M |
| Return on Assets (TTM) | -96.85% |
| Return on Equity (TTM) | -198.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Biohaven Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 2.50 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.97% |
| % Held by Institutions | 91.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Dec 2024 | 5,620,271 |
| Bellevue Group Ag | 31 Dec 2024 | 2,040,853 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 68.00 (JP Morgan, 190.60%) | Buy |
| Median | 62.00 (164.96%) | |
| Low | 54.00 (HC Wainwright & Co., 130.77%) | Buy |
| Average | 61.33 (162.09%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 31.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 28 Apr 2025 | 57.00 (143.59%) | Buy | 23.40 |
| Morgan Stanley | 07 Mar 2025 | 63.00 (169.23%) | Buy | 29.86 |
| JP Morgan | 05 Mar 2025 | 68.00 (190.60%) | Buy | 30.97 |
| HC Wainwright & Co. | 04 Mar 2025 | 54.00 (130.77%) | Buy | 31.37 |
| RBC Capital | 04 Mar 2025 | 61.00 (160.68%) | Buy | 31.37 |
| Deutsche Bank | 11 Feb 2025 | 65.00 (177.78%) | Buy | 42.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Apr 2025 | Announcement | Biohaven Announces Investment up to $600 Million by Oberland Capital |
| 05 Apr 2025 | Announcement | Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting |
| 03 Mar 2025 | Announcement | Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 |
| 03 Mar 2025 | Announcement | Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results |
| 11 Feb 2025 | Announcement | Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |